Eddy, S.F., Kane, S.E. and Sonenshein, G.E. (2007) Trastuzumab resistant Her2-driven breast cancer cells are sensitive to epigallocatechin-3 gallate. Cancer Res. 67: 9018-23.
Sadava, D., Whitlock, E. and Kane, S.E. (2007) The green tea polyphenol, epigallocatechin-3-gallate inhibits telomerase and induces apoptosis in drug-resistant lung cancer cells. Biochem. Biophys. Res. Comm. 360: 233-237.
Kane, S.E. (2006) Cancer therapies targeted to the epidermal growth factor receptor and its family members. Expert Opin. Ther. Patents 16: in press. Invited review.
Chan, C.T., Metz, M.Z. and Kane, S.E. (2005) Differential sensitivities of trastuzumab (Herceptin)-resistant human breast cancer cells to phosphoinositide-3 kinase (PI-3K) and epidermal growth factor receptor (EGFR) kinase inhibitors. Breast Cancer Res. Treat. 91: 187-201.
Schwarz, R.E., Donohue, C.A., Sadava, D., and Kane, S.E. (2003) Pancreatic cancer in vitro toxicity mediated by Chinese herbs SPES and PC-SPES: implications for monotherapy and combination treatment. Cancer Lett. 189: 59-68.
Sadava, D., Coleman, A.B. and Kane, S.E. (2002) Liposomal daunorubicin overcomes drug resistance in human breast, ovarian and lung carcinoma cells. J. Liposome Res. 12: 301-309.
Coleman, A.B., Metz, M.Z., Donohue, C.A., Schwarz, R.E., and Kane, S.E. (2002) Chemosensitization by fibroblast growth factor-2 is not dependent on proliferation, S-phase accumulation or p53 status. Biochem. Pharmacol. 64: 1111-1123.
Sadava, D., Ahn, J., Zhan, M., Pang, M.-L., Ding, J., and Kane, S.E. (2002) Effects of four Chinese herbal extracts on drug-sensitive and multidrug-resistant small-cell lung carcinoma cells. Cancer Chemother. Pharmacol. 49: 261-266.
Sadava, D., Phillips, T., Lin, C. and Kane, S.E. (2002) Transferrin overcomes drug resistance to artemisinin in human small-cell lung carcinoma cells. Cancer Lett. 179: 151-156.
Kane, S.E., Matsumoto, L., Metz, M.Z., Donohue, C.A., Lingeman, R.G., Lin, S.W., and Doroshow, J.H. (2001) MDR1 bicistronic vectors: Analysis of selection stringency, amplified gene expression, and vector stability in cell lines. Biochem. Pharmacol. 62: 693-704.
Coleman, A.B., Momand, J., and Kane, S.E. (2000) Basic fibroblast growth factor sensitizes NIH 3T3 cells to apoptosis induced by cisplatin. Molec. Pharmacol. 57: 324-333.
Metz, M.Z., Pichler, A., Kuchler, K., and Kane, S.E. (1998) Construction and characterization of single-transcript tricistronic retroviral vectors using two internal ribosome entry sites. Som. Cell Mol. Genet. 24: 53-69.
Lingeman, R.G., Joy, D.S., Sherman, M.A., and Kane, S.E. (1998) Effect of carbohydrate position on lysosomal transport of procathepsin L. Mol. Biol. Cell 9: 1135-1147.
Kane, S.E. (1997) Selection of transfected cells and co-amplification of transfected genes. In “Methods in Molecular Biology” (R. Tuan, ed.), Humana Press, Totowa, NJ. Vol. 62: pp. 359-367. Invited review.
Kane, S.E. (1996) Multidrug resistance of cancer cells. In “Advances in Drug Research” (B. Testa and U.A. Meyer, eds.), Academic Press, Ltd., London. Vol 28: pp. 182-252. Invited review.
Metz, M.Z., Matsumoto, L., Winters, K.A., Doroshow, J.H., and Kane, S.E. (1996) Bicistronic and two-gene vectors for using MDR1 as a selectable marker and therapeutic gene. Virology 217: 230-241.
Doroshow, J.H., Metz, M.Z., Winters, K.A., Matsumoto, L., Sakai, M., Muramatsu, M., and Kane, S.E. (1995) Transduction of NIH 3T3 cells with a retrovirus carrying both human MDR1 and glutathione S-transferase ? produces broad-range multidrug resistance. Cancer Res. 55: 4073-4078.
Metz, M.Z., Best, D.M., and Kane, S.E. (1995) Harvey murine sarcoma virus/MDR1 retroviral vectors: efficient virus production and foreign gene transduction using MDR1 as a selectable marker. Virology 208: 634-643.
Kane, S.E. (1993) Mouse procathepsin L lacking a functional glycosylation site is properly folded, stable, and secreted by NIH 3T3 cells. J. Biol. Chem. 268: 11456-11462.
This is a partial list. Full publications list available upon request. Information on this page may be self-reported and is subject to change at any time. Last updated: 07/08.